PDCD1LG2 and melanoma: In a study of melanoma, Inoue et al. [44] characterized the immune microenvironment of patients before and after treatment with nivolumab and found that patients with high levels of PD-L1, PD-L2, GZMA, and HLA-A expression had a high response rate after immunotherapeutic treatment with nivolumab.